An Open-Label Rater-Blinded Randomized Trial of Vilazodone versus Escitalopram in Major Depression

BACKGROUND: Vilazodone, a novel selective serotonin reuptake inhibitor and 5-HT1A partial agonist, was approved in 2011 for treatment for major depression. We aimed to compare the efficacy and safety of vilazodone versus escitalopram in patients with major depression at 4 weeks. METHODS: Participant...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Pattath Narayanan Suresh, Suresh, Rohith, Menon, Vikas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896102/
https://www.ncbi.nlm.nih.gov/pubmed/36778613
http://dx.doi.org/10.1177/02537176221127162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896102/
https://www.ncbi.nlm.nih.gov/pubmed/36778613
http://dx.doi.org/10.1177/02537176221127162

Ejemplares similares